Endometrial Cancer - Pipeline Review, H2 2013


#172048

139pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, Endometrial Cancer Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Endometrial Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Endometrial Cancer. Endometrial Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Endometrial Cancer.
  • A review of the Endometrial Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Endometrial Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Endometrial Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Endometrial Cancer 10
Endometrial Cancer Therapeutics under Development by Companies 12
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Endometrial Cancer Therapeutics Products under Development by Companies 18
Companies Involved in Endometrial Cancer Therapeutics Development 20
Bristol-Myers Squibb Company 20
Boehringer Ingelheim GmbH 21
GlaxoSmithKline plc 22
Genentech, Inc. 23
Merck & Co., Inc. 24
Ipsen S.A. 25
Novartis AG 26
Eisai Co., Ltd. 27
ImmunoGen, Inc. 28
Pfizer Inc. 29
Taiho Pharmaceutical Co., Ltd. 30
Exelixis, Inc. 31
AEterna Zentaris Inc. 32
Ariad Pharmaceuticals, Inc. 33
Critical Outcome Technologies Inc. 34
RXi Pharmaceuticals Corporation 35
Oryzon 36
Acceleron Pharma, Inc. 37
Esperance Pharmaceuticals, Inc. 38
Anaphore, Inc. 39
Aragon Pharmaceuticals, Inc. 40
Pharmsynthez 41
Endometrial Cancer Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
AEZS-108 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
lenvatinib - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
MK-2206 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
RG-7422 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
PF-05212384 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ridaforolimus - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
dalantercept - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
cabozantinib - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
COTI-2 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
nintedanib - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
EP-100 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
dovitinib lactate - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
buparlisib - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
GSK-2141795 + trametinib - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
AEZS-132 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ixabepilone - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
X-480 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
EP-200 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
IMGN-853 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
RYI-008 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
onapristone - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
mAb For Endometrial Cancer - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
ONCO-101 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
TAS-2985 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
ARN-912 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
AEZS-138 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
(ponatinib + ridaforolimus) - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Virexxa - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Virexxa - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Endometrial Cancer Therapeutics Drug Profile Updates 95
Endometrial Cancer Therapeutics Discontinued Products 128
Endometrial Cancer Therapeutics - Dormant Products 129
Endometrial Cancer Product Development Milestones 130
Featured News & Press Releases 130
Jun 11, 2013: Critical Outcome Technologies Announces Positive Preclinical Results Of Cancer Drug Candidiate COTI-2 Against p53 Gene Mutations 130
May 31, 2013: Kevelt To Produce Virexxa For Treatment Of Advanced And Relapsing Endometrial Cancer 131
May 17, 2013: Eisai To Present Clinical Data On Lenvatinib At ASCO Annual Meeting 131
May 15, 2013: Arno Therapeutics To Present Positive New Data On Onapristone In Endometrial And Breast Cancers At ASCO 2013 Annual Meeting 132
Apr 10, 2013: Aeterna Zentaris Presents Updated Data On LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates At AACR Meeting 2013 134
Apr 03, 2013: Aeterna Zentaris To Present Update On LHRH Receptor-targeted Disorazol Z Cytotoxic Conjugates At Upcoming AACR Annual Meeting 135
Mar 20, 2013: Ariad Pharma Announces Presentations Of Preclinical Data On Iclusig At AACR Annual Meeting 135
Dec 28, 2012: Aeterna Zentaris Receives Special Protocol Assessment From FDA For Phase III Registration Trial In Endometrial Cancer With AEZS-108 136
Nov 14, 2012: Acceleron Announces Initiation Of Gynecologic Oncology Group Phase II Clinical Trial Of Dalantercept In Patients With Endometrial Cancer 136
Aug 02, 2012: MethylGene Provides Update On MGCD265 Clinical Development 137

Appendix 138
Methodology 138
Coverage 138
Secondary Research 138
Primary Research 138
Expert Panel Validation 138
Contact Us 139
Disclaimer 139

Number of Products Under Development for Endometrial Cancer, H2 2013 10
Products under Development for Endometrial Cancer Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Comparative Analysis by Late Stage Development, H2 2013 14
Comparative Analysis by Mid Clinical Stage Development, H2 2013 15
Comparative Analysis by Early Clinical Stage Development, H2 2013 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 17
Products under Development by Companies, H2 2013 18
Products under Development by Companies, H2 2013 (Contd..1) 19
Bristol-Myers Squibb Company, H2 2013 20
Boehringer Ingelheim GmbH, H2 2013 21
GlaxoSmithKline plc, H2 2013 22
Genentech, Inc., H2 2013 23
Merck & Co., Inc., H2 2013 24
Ipsen S.A., H2 2013 25
Novartis AG, H2 2013 26
Eisai Co., Ltd., H2 2013 27
ImmunoGen, Inc., H2 2013 28
Pfizer Inc., H2 2013 29
Taiho Pharmaceutical Co., Ltd., H2 2013 30
Exelixis, Inc., H2 2013 31
AEterna Zentaris Inc., H2 2013 32
Ariad Pharmaceuticals, Inc., H2 2013 33
Critical Outcome Technologies Inc., H2 2013 34
Oryzon, H2 2013 36
Acceleron Pharma, Inc., H2 2013 37
Esperance Pharmaceuticals, Inc., H2 2013 38
Anaphore, Inc., H2 2013 39
Aragon Pharmaceuticals, Inc., H2 2013 40
Pharmsynthez, H2 2013 41
Assessment by Monotherapy Products, H2 2013 42
Assessment by Combination Products, H2 2013 43
Assessment by Stage and Route of Administration, H2 2013 45
Assessment by Stage and Molecule Type, H2 2013 47
Endometrial Cancer Therapeutics Drug Profile Updates 95
Endometrial Cancer Therapeutics Discontinued Products 128
Endometrial Cancer Therapeutics Dormant Products 129
Number of Products under Development for Endometrial Cancer, H2 2013 10
Products under Development for Endometrial Cancer Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Late Stage Products, H2 2013 14
Mid Clinical Stage Products, H2 2013 15
Early Clinical Stage Products, H2 2013 16
Discovery and Pre-Clinical Stage Products, H2 2013 17
Assessment by Monotherapy Products, H2 2013 42
Assessment by Combination Products, H2 2013 43
Assessment by Route of Administration, H2 2013 44
Assessment by Stage and Route of Administration, H2 2013 45
Assessment by Molecule Type, H2 2013 46
Assessment by Stage and Molecule Type, H2 2013 47